Drug Shortage Report for EMGALITY

Last updated on 2025-03-11 History
Report ID 250079
Drug Identification Number 02505134
Brand name EMGALITY
Common or Proper name galcanezumab injection
Company Name ELI LILLY CANADA INC
Market Status MARKETED
Active Ingredient(s) GALCANEZUMAB
Strength(s) 100MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes Carton package containing three 100 mg/mL prefilled syringes
ATC code N02CD
ATC description
Reason for shortage Delay in shipping of the drug.
Anticipated start date
Actual start date 2025-02-05
Estimated end date 2025-03-10
Actual end date 2025-03-10
Shortage status Resolved
Updated date 2025-03-11
Company comments For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Health Canada comments
Tier 3 Status No
Contact Address EXCHANGE TOWER, 130 KING STREET WEST
TORONTO, ONTARIO
CANADA M5X 1B1
Company contact information Lilly Canada’s Customer Response Centre 1-888-545-5972.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v7 2025-03-11 English Compare
v6 2025-03-10 French Compare
v5 2025-03-10 English Compare
v4 2025-02-26 French Compare
v3 2025-02-26 English Compare
v2 2025-02-10 French Compare
v1 2025-02-10 English Compare

Showing 1 to 7 of 7